NCT05927857 2026-04-09
Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
National Health Research Institutes, Taiwan
Phase 1/2 Recruiting
National Health Research Institutes, Taiwan
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
AstraZeneca
Yonsei University